According to Kalorama Information’s 2022 molecular diagostics report [https://kaloramainformation.com/product/the-world-market-for-molecular-diagnostics-tests-11th-edition/], the market now exceed 21 billion. The demand for molecular IVD means that very often a single firm cannot go it alone and must find partners.
These are partnerships involving 20 companies that have just occurred in recent months:
Immucor and Pirche: a multi-year partnership to expand Immucor’s transplant diagnostics software; Immucor makes investment in Pirche; goal to provide users a seamless and direct interface with the Pirche epitope matching prediction pipeline in their transplant analysis software
Qiagen Neuron23 an agreement to develop a NGS based companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson’s disease; planned to be developed using the NextSeq 500 System
QuantuMDx and Sansure Biotech global R&D, manufacturing and commercial partnership aimed to bring a comprehensive array of molecular diagnostic assays to the Q-POC platform; Sansure gets exclusive rights to Q-POC in China, for which QuantuMDx receives licensing and royalty payments; QuantuMDx will have the exclusive rights to sell Sansure-translated assays outside China
Bio-Rad and Curiosity Diagnostics acquiring Curiosity for total consideration of up to $170 M, consisting of approximately $100 M in cash, and up to $70 M in future milestone payments
“According to Kalorama Information’s 2022 molecular diagnostics report, the market now exceeds 21 billion. The demand for molecular IVD means that very often a single firm cannot go it alone and must find partners.”Kalorama Information
Roche and Amoy Diagnostics: strategic partnership; jointly promote the development of an open, cooperative and innovative medical and health ecosystem and provide patients with more accurate digital medical solutions
Bio-Rad and 10x Genomics: companies agree to global patent cross-licensing for patents held by Bio-Rad and 10x Genomics, resolving outstanding legal issues in the field of single-cell genomics; non-exclusive, worldwide, royalty-bearing license to develop products and services related to single-cell analysis
Meridian Bioscience and SD Biosensor and SJL Partners: definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an all-cash transaction valued at approximately $1.53 billion.
AstraZeneca and Biocartis: development of a novel companion diagnostic test on Biocartis’ molecular Idylla platform, for use with Tagrisso (osimertinib), AstraZeneca’s third-generation EGFR-TKI (tyrosine kinase inhibitor) treatment”
Cepheid BioGX: collaboration to deliver a PCR test for monkeypox that will run on the GeneXpert system
Exact Sciences Ultima Genomics: Ultima Genomics will provide access to its NGS products, which are based on a new architecture designed to enable sequencing at a fraction of the cost of other technologies; develop one or more of Exact Sciences’ advanced cancer diagnostic tests using Ultima’s sequencing technology; Exact Sciences investing in Ultima